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As part of the UK NCRI AML17 trial, adult patients with acutemyeloid leukemia in remission could be randomized to receivethe mammalian target of rapamycin inhibitor everolimus, sequen-
tially with post-induction chemotherapy. Three hundred and thirty-nine
patients were randomised (2:1) to receive everolimus or not for a maxi-
mum of 84 days between chemotherapy courses. The primary endpoint
was relapse-free survival. At 5 years there was no difference in relapse-
free survival [29% versus 40%; odds ratio 1.19 (0.9-1.59) P=0.2], cumula-
tive incidence of relapse  [60% versus 54%: odds ratio 1.12 (0.82-1.52):
P=0.5] or overall survival [45% versus 58%: odds ratio 1.3 (0.94-1.81):
P=0.11]. The independent Data Monitoring Committee advised study
termination after randomization of 339 of the intended 600 patients
because of excess mortality in the everolimus arm without any evidence
of beneficial disease control. The delivery of the everolimus dose was
variable, but there was no evidence of clinical benefit in patients with
adequate dose delivery compared with no treatment. This study suggests
that the addition of mammalian target of rapamycin inhibition to
chemotherapy provides no benefit.
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ABSTRACT
Introduction
The majority (70-85%) of younger patients with acute myeloid leukemia (AML)
will enter complete morphological remission with any one of a variety of induction
treatments. However, nearly half will relapse. It is being increasingly recognized
that a substantial proportion of those subjects in morphological remission do actu-
ally have residual disease, as determined by techniques of minimal/measurable
residual disease assessment (flow cytometry or quantitative polymerase chain reac-
tion1,2). In our previous studies we endeavored to define the optimum post-remis-
sion chemotherapy. To date we have concluded that, apart from transplantation,
following two induction courses of anthracycline-containing therapy, two consoli-
dation courses of cytarabine (Ara-C) is adequate.3 One of the aims of the UK NCRI
AML17 trial was to explore the effects of a further reduction in the total number of
chemotherapy courses from four to three, as well as the addition of molecularly tar-
geted treatments to consolidation therapy. Among these was the incorporation of
the inhibitor of the mammalian target of rapamycin (mTOR), everolimus.
There is plausible pre-clinical evidence both in vitro and
in vivo that mTOR inhibition could be beneficial in AML.
mTOR is a serine/threonine protein kinase that is predom-
inantly modulated by PI3K-AKT-dependent mechanisms
and acts as a central regulator of cellular metabolism,
growth and survival.4 Dysregulation of the mTOR path-
way is closely associated with cancers including AML,5,6
and other human diseases. Part of the rationale is the evi-
dence of constitutive activation of the PI3K-AKT pathway
in 90% of AML samples and the demonstration that this
activation is central to the survival of AML blasts but not
to that of normal CD34+ cells.7 The concept that
everolimus may have the potential to eliminate leukemia-
initiating stem cells while sparing normal hematopoietic
stem cells is also appealing. In vivo evidence in NOD/SCID
mice has suggested that mTOR regulates a critical cell sur-
vival pathway in AML stem cells.8,9 In preliminary unran-
domized clinical trial, the mTOR inhibitor sirolimus was
administered as a single agent to nine relapsed, refractory
or poor-risk AML patients for 28 days resulting in partial
responses in four, and stable disease in a fifth patient.10
Dephosphorylation of downstream effectors of mTOR
was demonstrated. In an ongoing UK trial, 11 elderly
patients with primary, relapsed AML have been treated
with the combination of low-dose Ara-C and sirolimus.
Following a single 28-day course of treatment, of the
seven patients eligible for analysis, one had achieved a
complete remission, four had obtained a partial remission,
one had profoundly hypocellular bone marrow and one
patient was a non-responder (Das Gupta, unpublished
data). Patients in this trial reliably maintained trough
sirolimus levels of 8-16 ng/mL, which are consistent with
the published concentrations required to inhibit AML cell
growth in vitro. The feasibility of combining mTOR inhi-
bition (sirolimus) with intensive chemotherapy had also
been assessed in AML patients in conjunction with the
more intensive MEC (mitoxantrone, etoposide and cytara-
bine) chemotherapy regimen in a phase I dose escalation
study and reported in abstract form. In this study standard
renal transplant doses of sirolimus were well tolerated and
did not increase the non-hematologic toxicity of MEC
chemotherapy with a median time to neutrophil recovery
of 27 days.11 Based on this background information, the
NCRI AML17 trial included the option for eligible patients
to be randomized to receive, or not, the mTOR inhibitor
everolimus daily between consolidation chemotherapy
courses.
Methods
The UK NCRI AML 17 trial  (ISRNCTN 55675535) was a large,
prospective, phase 3, multicenter trial for patients with newly-
diagnosed AML or high-risk myelodysplastic syndrome (>10%
marrow blasts), generally under the age of 60 years, open from
April 2009 to December 2014 in more than 130 centers in the
United Kingdom, Denmark and New Zealand. Through random-
ization of the participants, it addressed several issues (Online
Supplementary Figure S1). Between October 2009 and October
2012, 499 adult patients who did not have acute promyelocytic
leukemia had received a first induction course of treatment: those
who did not have core-binding factor leukemia, high-risk disease
(defined using a multifactorial score12) and were not in the lestau-
rtinib randomization for patients with FLT3 mutations, could be
randomized to receive everolimus, or not, in a 2:1 ratio, between
subsequent consolidation chemotherapy courses. The treatment
schedules have been set out elsewhere.13 Allogeneic stem cell
transplantation was permitted for patients with intermediate- or
poor-risk disease with a recommendation of myelo-ablative con-
ditioning for patients aged <35 years and reduced intensity condi-
tioning for intermediate-risk patients aged >45 years, with inves-
tigators able to choose an ablative or reduced intensity approach
for patients between 35 and 45 years. 
Of all adult patients entering the AML17 trial while the
everolimus randomization was available, 34% were eligible for
such randomization. These patients were randomized to receive,
or not, oral everolimus (10 mg daily from 2 days after each
chemotherapy course for up to 28 days or until 2 days before the
start of the subsequent course, whichever was shorter) between
each course of consolidation chemotherapy. In patients allocated
three courses of treatment, a final 28-day course of everolimus
was given after a 1-week break. In patients with side effects
thought to be due to everolimus, subsequent daily doses could be
reduced by 50%. If this did not improve tolerability, dosing could
be further reduced to alternate days; if these reduced doses were
not tolerated, subsequent doses were to be omitted. After 65%
(n=146) of the patients randomized to everolimus had been
assessed, the independent data monitoring committee recom-
mended, because of increased side effects and reduced compli-
ance, that the starting daily dose of everolimus be reduced to 5 mg
with the option to increase to 10 mg if well-tolerated.
Extensive Sanger sequencing (111 genes) was undertaken in 123
patients;  NPM1 status was available in 302 patients.  
Patients were requested to provide a trough blood sample taken
immediately prior to everolimus dosing on day 14 of each treat-
ment course to measure the level of mTOR inhibitory activity in
their plasma. The methods for measuring this activity are summa-
rized in Online Supplementary Figure S2 and will be reported more
fully elsewhere.
Statistical considerations
All analyses are on an intention-to-treat basis. Categorical end-
points were compared using Mantel-Haenszel tests, giving Peto
odds ratios and confidence intervals. Continuous/scale variables
were analyzed by Wilcoxon rank sum tests and time-to-event out-
comes using the log-rank test, with Kaplan-Meier survival curves.
Odds/hazard ratios (OR/HR) <1 indicate benefit for everolimus.
All survival percentages refer to 5 years unless otherwise stated.
Stratified analyses were performed with suitable tests for inter-
action14 and interpreted cautiously. 
It was planned to recruit 600 patients to the everolimus ran-
domization, which would have given 85% power to detect a
12.5% difference in the primary endpoint of relapse-free survival,
from 50% to 62.5% (HR 0.68). Follow-up is complete until March
1st, 2016 [median follow-up from diagnosis 53.5 months (range,
4.3 – 76.8 months)]. 
The trial was conducted in accordance with the Declaration of
Helsinki, sponsored by Cardiff University and approved by Wales
REC3 on behalf of all UK investigators, by the Danish Medicines
Agency for sites in Denmark, and by MEDSAFE for sites in New
Zealand. 
Results
Patients’ characteristics 
The randomization opened in October 2009. In 2012,
the independent data monitoring committee recommend-
ed closure of the randomization because of an excess of
early mortality in remission with everolimus and no asso-
Everolimus added to consolidation therapy  for AML
haematologica | 2018; 103(10) 1655
ciated evidence of relapse reduction. Between October
2009 and October 2012, 332 of 482 eligible patients were
randomized (Figure 1). Their characteristics are shown in
Table 1. There were no significant differences in survival
outcomes between eligible patients who entered the ran-
domization and those who did not (P=0.8), although
patients with higher white blood cell counts, worse per-
formance status and secondary disease were marginally
less likely to enter the randomization. The median age
was 47 years (range, 16-69). The majority presented with
de novo AML and had a WHO performance score of <2.
The other protocol treatments given to patients in the
everolimus randomization are shown in Table 1. In addi-
tion to standard daunorubicin/Ara-C induction, etoposide
and gemtuzumab ozogamicin was given to 43% and 45%
of patients, respectively, in induction with no difference
between the arms. 
Overall, 132/332 (40%) of patients received a transplant
(everolimus 39%, control 42%, P=0.6), with a minority of
these (34/132) being allografts in first remission (20 versus
14, P=0.3). There was no evidence of differences in trans-
plantation rates or types of transplants between the arms
(any stem cell transplant 39% versus 42%, P=0.6; allograft
31% versus 34%, P=0.6; allograft in first complete remis-
sion 9% versus 13%, P=0.3) (Table 1). 
Extensive Sanger sequencing (111 genes) was undertak-
en in 123 patients: the gene panel and distribution are
shown in Online Supplementary Figure S3. In addition
NPM1 status, determined using previously published
methods, was known for 302 patients. 
Treatment compliance
Of the 220 patients allocated to receive everolimus, 16
never started therapy. Approximately 25% of patients did
not receive 14 days of everolimus; about half completed
the first 28-day course. At the time of the second course of
everolimus (course 3 of chemotherapy), 35% of patients
for whom information on the second everolimus course
was available did not receive the drug (Figure 2). Reasons
were given for about two-thirds of patients (39/61): 11
patients had not completed the previous course; 11
patients chose to discontinue the therapy (often because
of toxicity in the previous course); in three cases the data
monitoring committee had recommended closure of the
study with cessation of everolimus treatment; in five cases
patients did not reach the starting point for everolimus
therapy on protocol; in two cases the clinician decided,
and in four other cases, everolimus was not given due to a
variety of toxicities. 
Toxicity 
The recorded toxicities are shown in Figure 3. There
were more hematologic toxicities in the everolimus arm
and these were most obvious after the first everolimus
course, with a median time to platelet count recovery to
>100x109/L being 9 days longer (39 versus 29 days;
P=0.006); this was reflected by a significantly greater
requirement for platelet support (Table 3). The kinetics of
neutrophil recovery was unaffected by everolimus, but
there was significantly more use of antibiotics and a
longer stay in hospital with the first course of everolimus,
as well as increased oral toxicity (course 1) and higher ala-
nine transaminase levels (course 2). 
Cumulative risk of relapse and death in remission 
The overall outcomes are shown in Table 2. The cumu-
lative incidence of relapse at 5 years (Figure 4A) did not
differ significantly between arms [60% versus 54%, HR
1.12 (0.82-1.52), P=0.5]. There was a significant excess of
deaths in remission in the everolimus arm in the first 6
A.K. Burnett et al.
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Figure 1. CONSORT diagram. APL: acute promyelocytic leukemia; CEP-701: lestaurtinib; CBF: core-binding factor; MTOR: mammalian target of rapamycin; 
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months following randomization [8% versus 1%, HR 3.57
(1.36-9.42), P=0.009], with no significant differences
thereafter, leading to a non-significant excess of overall
mortality with everolimus [11% versus 6%, HR 1.75 (0.83-
3.70), P=0.14] (Figure 4B). In the first 6 months there were
17 deaths in remission in the everolimus arm versus 1
death in the control arm: the causes of these deaths were
infection (9 versus 1), infection + hemorrhage (3 versus 0),
hemorrhage/cardiovascular accident (3 versus 0), cardiac (1
versus 0) and multiple (1 versus 0). Beyond 6 months, there
were six deaths in each of the two arms, with the causes
of these deaths in remission being infection (1 versus 1),
cardiac (1 versus 0), hepatic (1 versus 0), second cancer (1
versus 0), graft-versus-host disease (0 versus 1), multiple (0
versus 2) and unknown/other (2 versus 2).
Relapse-free and overall survival 
Both relapse-free and overall survival rates were non-
significantly inferior in the everolimus arm (Figure 4C,D),
reflecting the adverse hazard ratios for both relapse and
death in remission, with no evidence of differences in sal-
vage between arms after relapse [relapse-free survival:
29% versus 40%, HR 1.19 (0.90-1.59), P=0.2; overall sur-
vival: 45% versus 58%, HR 1.30 (0.94-1.81), P=0.11]. A
sensitivity analysis censoring patients at the time of stem
cell transplantation showed results which were consistent
with the overall analysis (Table 2).
Exploratory analyses 
Correlations with everolimus plasma inhibitory activi-
ty, determined by the assay used in this study, did not
show convincing patterns. Even patients whose samples
showed deep and sustained inhibition did not have an
associated reduction in relapse (Online Supplementary
Figure S2). There was no relationship between the level
of inhibition and toxicity or excess mortality. Prior induc-
tion chemotherapy, age, gender, white blood cell count,
and minimal residual disease status after course one all
had no impact on outcomes (Online Supplementary Figure
S4A). In addition no relationship was found between
other treatment modalities given and response, and no
gene mutation, including the 111 genes assayed by
Sanger sequencing in 123 patients, was shown to be
associated with a differential response (Online
Supplementary Figure S5). Because of concerns about com-
pliance with everolimus treatment, relapse-free survival
was compared between patients with satisfactory drug
delivery (defined as at least 14 days of treatment per
course), those with inadequate drug delivery (less than
14 days treatment per course) and those allocated to no
Table 1. Patients’ characteristics.
Characteristic        Everolimus (n=220)                      Control (n=112)
Age, years
16-29                                  33 (15%)                                            16 (14%)
30-39                                  36 (16%)                                            17 (15%)
40-49                                  58 (26%)                                            31 (28%)
50-59                                  73 (33%)                                            37 (33%)
60+                                     20 (9%)                                             11 (10%)
Median                                    48                                                        46
Range                                    16-69                                                        
Sex
Female                             117 (53%)                                           70 (63%)
Male                                  103 (47%)                                           42 (37%)
Diagnosis
De novo                            203 (92%)                                          103 (92%)
Secondary                          5 (2%)                                                3 (3%)
MDS                                    12 (5%)                                               6 (5%)
WHO performance status
0
1                                               178                                                        88
2                                                37                                                         19
3                                                 4                                                           3
4                                                 1                                                           2
White blood cell count, x109/L
0-9.9                                  138 (63%)                                           65 (58%)
10-49.9                               61 (28%)                                            34 (30%)
50-99.9                                15 (7%)                                               9 (8%)
100+                                    6 (3%)                                                4 (4%)
Median                                    5.8                                                        5.5
Range                                 0.4-177.7                                             0.5-249.0
Cytogenetics
Intermediate                  194 (88%)                                          106 (95%)
Unknown                          26 (12%)                                              6 (5%)
FLT3 ITD
Wild/type                         199 (96%)                                          101 (99%)
Mutant                                 8 (4%)                                                1 (1%)
Unknown                                 13                                                         10
Characteristic        Everolimus (n=220)                      Control (n=112)
NPM1c
Wild type                         132 (65%)                                           61 (61%)
Mutant                              70 (35%)                                            39 (39%)
Unknown                                 18                                                         12
FLT3 TKD
Wild type                         204 (99%)                                          100 (98%)
Mutant                                 3 (1%)                                                2 (2%)
Unknown                                 13                                                         10
Induction chemotherapy
ADE (not randomized)  13 (6%)                                               7 (6%)
ADE                                    29 (13%)                                            14 (13%)
ADE+GO3                        26 (12%)                                            14 (13%)
ADE+GO6                        26 (12%)                                            14 (13%)
DA+GO3                           22 (10%)                                            11 (10%)
DA+GO6                           26 (12%)                                            12 (11%)
DA 90 mg                          37 (17%)                                            19 (17%)
DA 60 mg                          41 (19%)                                            21 (19%)
Risk score after course 1
Good risk                          27 (13%)                                            11 (10%)
Standard risk                  193 (87%)                                          101 (90%)
MRD status after course 1 (CR only)
CR, MRD -ve                    43 (20%)                                            24 (21%)
CR, MRD +ve                   63 (29%)                                            24 (21%)
No MRD data/no CR      114 (52%)                                           64 (57%)
Transplanted                      85 (39%)                                            47 (42%)
Any allograft                     69 (31%)                                            38 (34%)
Any transplant in CR1    24 (11%)                                            16 (14%)
Allograft in CR1                20 (9%)                                             14 (13%)
MDS: myelodysplastic syndrome; WHO: World Health Organization; ITD: internal tan-
dem duplication; TKD: tyrosine kinase domain; ADE: Ara-C, daunorubicin, etoposide;
GO: gemtuzumab ozogamicin; DA: daunorubicin; CR: complete remission; MRD: min-
imal residual disease;
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Figure 3. Toxicities associated with treatment in courses 2 and 3. (A) Course 2 (B) Course 3.
A B
Figure 2. Compliance with treatment. AE: adverse event; LFT: liver fuction tests.
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treatment. Although patients in whom drug delivery was
inadequate (n=85) had a worse relapse-free survival
(29%) there was no difference in relapse-free survival
between patients with satisfactory drug delivery (n=63)
at 41% and no everolimus treatment (n=99) at 40%
(Online Supplementary Figure S4).
Discussion
In this trial there was no benefit of the addition of
everolimus to post-induction chemotherapy, despite the
pre-clinical in vitro and in vivo rationale for the use of this
mTOR inhibitor. The main explanations appear to be the
Table 2. Clinical outcomes by treatment arm.
                                           Everolimus     Control         OR/HR & CI       P-value
CR/CRi                                              99%                99%            1.02 (0.09-11.2)           1.0
MRD positivity after                     63%                65%            1.07 (0.50-2.33)           0.9
course 2 (CR only)
30-day mortality                              1%                  1%             1.48 (0.19-11.7)           0.7
60-day mortality                              4%                  1%             2.77 (0.70-11.0)          0.15
5-year OS                                         45%                58%            1.30 (0.94-1.81)          0.11
5-year RFS                                       29%                40%            1.19 (0.90-1.59)           0.2
5-year cumulative                          60%                54%            1.12 (0.82-1.52)           0.5
incidence of relapse
6-month death in CR                      8%                  1%             3.57 (1.36-9.42)         0.009
5-year cumulative                          11%                 6%             1.75 (0.83-3.70)          0.14
incidence of death in CR                 
5-year survival after relapse       19%                30%            1.17 (0.81-1.70)           0.4
5-year OS censored at SCT         57%                66%            1.34 (0.87-2.06)          0.18
CR: complete remission; CRi: CR with incomplete blood count recovery; OS: overall survival;
RE: relapse-free survival; SCT: stem cell transplantation.
Figure 4. Relapse, death in remission, relapse-free survival and overall survival within the everolimus randomisation: (A) Cumulative incidence of relapse; (B) cumu-
lative incidence of death in remission; (C) relapse-free survival; (D) overall survival.
A B
C D
Table 3. Recovery and supportive care in everolimus randomization.
                                                   Randomization                        
Type of Care                          Course      Everolimus    Control     P-value
Neutrophil recovery                      2                      28                   29               0.4†
(median days from
start of course)                               3                      29                   27              0.08†
Platelet recovery (median            2                      38                   29             0.006†
days from start of course)           3                      42                   36              0.10†
Blood (mean n. of units)              2                     4.6                  5.0             0.08*
                                                             3                     6.3                  6.1              0.5*
Platelets (mean n. of units)         2                     5.1                  3.7            0.009*
                                                             3                     6.4                  5.5              0.4*
Antibiotics (mean days)                2                    10.2                 7.7            0.002*
                                                             3                    12.5                10.8            0.14*
Hospitalization (mean days)        2                    25.2                22.3            0.02*
                                                             3                    24.8                23.5             0.3*
Hospitalization (median days)    2                    25.5                 23
                                                             3                      25                 24.5
† Logrank test. * Wilcoxon test.
observed excess toxicity, which was primarily gastroin-
testinal (mucositis and diarrhea), and biochemical evi-
dence of liver toxicity at the dose chosen. Infection was a
major issue in the first 6 months of treatment with 12 ver-
sus 1 deaths attributed to infection in the everolimus and
control arms, respectively. This did not appear to be the
result of prolonged neutropenia but may be attributable to
the immunosuppressive effects of everolimus when given
with chemotherapy, which reflects what has been seen
with the use of the mTOR inhibitor in solid tumors.15 This
in turn contributed to sub-optimal drug delivery for many
patients. The chosen schedule of 10 mg daily was not fea-
sible in this setting, but drug delivery improved when a 5
mg daily dose was introduced. Other studies in leukemia
have used equivalent schedules16,17 or a loading dose (12
mg) followed by 4 mg/day for 7 days per cycle11 or lower
doses in combination with low-dose Ara-C.18 However
even when the subgroup of good compliers was compared
separately, there was no evidence of improved disease
control. 
We had hoped that the development of an assay to
quantitate plasma inhibitory activity would provide
insight into response or toxicity, but unlike the experience
of plasma inhibitory activity in the setting of an FLT3
inhibitor,19,20 consistent correlations were not found. In a
phase 2 study of patients with relapsed AML treated with
clofarabine and temsirolomus, correlation of response to
dephosphorylation of pS6RP (S6 ribosomal protein) was
demonstrated.21 However the target cells were the
patients’ own blasts, which were not available in the cur-
rent study and it was unclear whether the clinical out-
come was superior to that which clofarabine alone could
achieve.
Finally the mTOR inhibitors tested to date have been
inhibitors of the TORC1 pathway. This may be by-passed
by the TORC2 pathway which is insensitive to this class
of mTOR inhibitors, but may be sensitive to agents which
produce dual inhibition.
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